1. Home
  2. AMWD vs TBPH Comparison

AMWD vs TBPH Comparison

Compare AMWD & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Woodmark Corporation

AMWD

American Woodmark Corporation

HOLD

Current Price

$37.56

Market Cap

872.8M

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$13.86

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMWD
TBPH
Founded
1980
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Forest Products
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
872.8M
1.0B
IPO Year
1995
2013

Fundamental Metrics

Financial Performance
Metric
AMWD
TBPH
Price
$37.56
$13.86
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$63.50
$18.50
AVG Volume (30 Days)
197.2K
782.6K
Earning Date
02-26-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.88
Revenue
$1,709,585,000.00
$15,386,000.00
Revenue This Year
N/A
$70.90
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$15.75
Revenue Growth
N/A
N/A
52 Week Low
$37.56
$7.90
52 Week High
$72.16
$21.03

Technical Indicators

Market Signals
Indicator
AMWD
TBPH
Relative Strength Index (RSI) 20.25 27.74
Support Level N/A $13.41
Resistance Level $58.01 $14.76
Average True Range (ATR) 1.86 0.58
MACD -0.57 -0.08
Stochastic Oscillator 0.64 11.29

Price Performance

Historical Comparison
AMWD
TBPH

About AMWD American Woodmark Corporation

American Woodmark Corp manufactures and distributes cabinets and vanities for the remodeling and new home construction markets. It offers several products that fall into product lines including kitchen cabinetry, bath cabinetry, office cabinetry, home organization, and hardware. The products are sold under the brand names American Woodmark, Timberlake, Shenandoah Cabinetry, and Waypoint Living Spaces among others.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: